VolitionRX Limited (VNRX)
NYSE: VNRXHealth CareBiotechnology: In Vitro & In Vivo Diagnostic SubstancesUSD
At close: Nov 20, 4:00 PM ET · Delayed 15 min
VNRX stock chart
Technical analysisKey statistics
All statistics- Market cap
- $5.85M
- EPS (TTM)
- -$2.57
- Dividend yield
- None
- 52-week range
- 0.1555 – 7.80
- Day range
- 0.1555 – 0.17
- Volume / Avg
- 1.20M / 9.57M
- Beta
- —
- Shares outstanding
- 36.08M
52-week range
VNRX stock today
Shares of VolitionRX (VNRX) finished lower on Nov 20 at $0.1621, a drop of 1.58% or $0.0026 per share, versus the S&P 500's 3.70% decline. Trading was light, with 1.20M shares changing hands, about 13% of the average daily volume. At this level, VNRX sits near the bottom of its 52-week range of $0.1555 to $7.80: 97.9% below the high and 4.2% above the low.
VolitionRX has posted a net loss over the last twelve months (EPS of -$2.57), so its P/E ratio is not meaningful.
Summary generated from market data by MetaCap's automated system. Methodology
About VolitionRX
Company profileVolitionRx Limited, a multi-national epigenetics company, develops blood tests to help detect and monitor a range of cancers, and diseases associated with NETosis in the United States, Europe, and Asia. The company offers Nu.Q Vet, a cancer screening test for dogs and other animals; Nu.Q Nets, detects diseases associated with NETosis, such as sepsis; Nu.Q Discover, a solution to profiling nucleosomes. It also provides Nu.Q Cancer for predicting treatment response, monitoring treatment response and disease progression, and amending a patient's cancer treatment regimen; and Capture-PCR and Capture-Seq, which are isolating and capturing circulating tumor-derived DNA from plasma samples for early cancer detection.
- Sector
- Health Care
- Industry
- Biotechnology: In Vitro & In Vivo Diagnostic Substances
- CEO
- Mr. Cameron Reynolds MBA
- Headquarters
- Henderson, NV
- Employees
- 57
- IPO year
- 2015
- Website
- volition.com
Financial highlights
Full financialsIn fiscal 2025, VolitionRX generated $1.7 million in revenue, up 40.0% from fiscal 2024, its 5th consecutive year of revenue growth. VolitionRX reported a net loss of $23.4 million, compared with a loss of $27.0 million a year earlier. Operating margin was -1258.5%.
| Fiscal year | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|
| Revenue | $1.73M | $1.23M | $775.30K | $306.39K | $90.03K |
| Growth | +40.04% | +59.10% | +153.04% | +240.30% | +570.25% |
| Net income | $-23.36M | $-26.97M | $-35.68M | $-30.60M | $-26.99M |
| EPS (diluted) | — | $-0.31 | $-0.50 | — | $-0.51 |
Analyst forecast
ForecastConsensus (5 analysts)
none
Avg. price target
$13.62+8302.22%
- Strong buy 1
- Buy 3
- Hold 1
- Sell 0
- Strong sell 0
Target range
Ratings and targets reflect third-party analyst opinions, not MetaCap recommendations.
Earnings
Earnings history- Last reported (Sep/2026)
- Nov 12, 2026
- EPS actual vs est.
- $-0.21 vs $-0.35
- Surprise
- +40.00%
VNRX news
All VNRX news- VolitionRx (VNRX) Q3 2026 Earnings Call TranscriptNasdaq
- VolitionRx Limited Announces Third Quarter 2026 Financial Results and Business UpdateNasdaq
- VolitionRx Limited CEO Cameron Reynolds Agrees to Further Temporary Salary Reduction to $236,970.50Nasdaq
- VolitionRx Limited Announces $500,000 Partial Prepayment of Convertible NoteNasdaqVNRX, BF.A
VolitionRX peers
Health Care sector| Company | Price | % Chg | Market cap | Compare |
|---|---|---|---|---|
| TRIBTrinity Biotech plc ADR | 6.24 | +13.76% | $5.07M | vs VNRX |
| BMRABiomerica Inc. | 1.08 | -0.92% | $4.97M | vs VNRX |
| CDIOCardio Diagnostics Holdings Inc. | 1.60 | -3.03% | $4.74M | vs VNRX |
| QCLSQ/C Technologies Inc. | 0.2784 | -6.01% | $2.40M | vs VNRX |
| VRAXVirax Biolabs Group Limited | 0.3319 | -12.89% | $446.40K | vs VNRX |
| IMDXInsight Molecular Diagnostics Inc. | 1.97 | +18.67% | $80.88M | vs VNRX |
| ICCCImmuCell Corporation | 10.92 | -2.41% | $99.28M | vs VNRX |
| NNNNAnbio Biotechnology Class A | 3.32 | -9.04% | $145.72M | vs VNRX |
Indexes, lists and sector
VolitionRX stock FAQ
What is VolitionRX's stock price today?
VNRX last traded at $0.1621 as of Nov 20, 4:00 PM EST, down 1.58% on the day. Prices are delayed at least 15 minutes.
Who is VolitionRX's CEO?
Mr. Cameron Reynolds MBA is the chief executive officer of VolitionRX Limited, which has about 57 employees.
What is the VNRX 52-week high?
The 52-week high for VNRX is $7.80 and the 52-week low is $0.1555. The stock is currently 97.9% below its high.